Deep Genomics vs Qure.ai

Qure.ai has a disclosed valuation of $270M, while Deep Genomics's valuation is not publicly available, making a direct size comparison difficult. Qure.ai employs 250 people.

Deep Genomics has raised more in total funding at $180M, compared to Qure.ai's $157M — a gap of $23M. Combined, the two companies have completed 5 known funding rounds.

Qure.ai holds the higher Awaira Score at 70/100, compared to Deep Genomics's 68/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 2-point gap that reflects meaningful differences in scale or traction.

Deep Genomics was founded by Brendan Frey in 2015. Qure.ai was founded by Prashant Warier in 2016. Visit each company's profile on Awaira for a full founder biography.

Deep Genomics: Deep Genomics applies deep learning to genetic medicine discovery, using AI models trained on genomic sequence data to predict the functional consequences of genetic variants, identify RNA splicing defects that underlie genetic diseases, and generate novel therapeutic candidates including antisense oligonucleotides and small molecules that correct disease-causing genetic variants. The Toronto company was founded by Brendan Frey, a University of Toronto machine learning professor who collaborated with Geoffrey Hinton on deep learning research.\n\nThe company raised approximately $180 million in venture funding from investors including True Ventures, AlleyCorp, and GV (Google Ventures). Deep Genomics has built an AI drug discovery platform called the AI Workbench that integrates genomic data, disease biology, and AI prediction across the therapeutic discovery pipeline, and has entered a strategic alliance with Agenus to develop cancer treatments using its AI-designed oligonucleotide candidates.\n\nDeep Genomics competes in the AI genetic medicine space against Recursion Pharmaceuticals, Insitro, Exscientia, and gene therapy companies building computational biology capabilities. Its specific focus on RNA biology and oligonucleotide therapeutics, which represent a growing class of approved genetic medicines, differentiates it from platforms focused on small molecule drug discovery or cell therapy. The Toronto University of Toronto AI ecosystem, including connections to the Vector Institute and the Hinton research lineage, provides research credibility and talent access that distinguishes Canadian AI drug discovery from international competitors. Qure.ai: Qure.ai is an Indian artificial intelligence company founded in 2016 that develops machine learning solutions for diagnostic imaging in healthcare. The company specializes in computer-aided detection and diagnosis systems that analyze medical imaging data including chest X-rays, CT scans, and mammograms to identify abnormalities and assist radiologists in clinical decision-making. Its platform uses deep learning algorithms trained on large datasets to detect conditions such as tuberculosis, COVID-19, lung cancer, and other pathologies. Qure.ai's products are deployed across hospitals and diagnostic centers in India and internationally, serving both institutional healthcare providers and diagnostic chains. The company has secured $157 million in total funding and operates at Series D stage with a valuation of $300 million as of recent rounds. Its technology addresses the shortage of radiologists in developing markets while improving diagnostic accuracy and turnaround times. Qure.ai competes in the medical AI space alongside companies like IBM Watson Health, Zebra Medical Vision, and various regional diagnostic AI providers. The company has demonstrated strong traction in the Indian healthcare market and has expanded its reach to international markets. Its growth trajectory reflects increasing adoption of AI-assisted diagnostic solutions globally and the rising demand for scalable healthcare technologies in resource-constrained settings. Qure.ai focuses specifically on diagnostic imaging AI for markets with radiologist shortages, positioning it distinctly within underserved geographies.

Deep Genomics was founded first in 2015, giving it 1 year of additional market experience. Qure.ai was founded later in 2016. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Deep Genomics has approximately 100-500 employees, while Qure.ai has approximately 250. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Deep Genomics and Qure.ai are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.